Literature DB >> 32422664

EASAPS/ESPRAS Considerations in getting back to work in Plastic Surgery with the COVID-19 Pandemic - A European point of view.

Ivar van Heijningen1, Konstantin Frank2, Francisco Almeida3, Urs Bösch4, Nicola Bradic5, Horacio Costa6, Cenk Demirdover7, Mark Henley8, Lars Peter Kamolz9, Michel Rouif10, Stephan Spendel9, Katharina Russe-Wilflingseder11, Birgit Stark12, Riccardo E Giunta2, Jose Carlos Parreira13, Rado Zic14.   

Abstract

The aim of this paper is to summarize the results of a consensus process and a European webinar of the two societies, European Association of Societies of Aesthetic Surgery (EASAPS) and the European Society of Plastic, Reconstructive and Aesthetic Societies (ESPRAS) on what is considered safe practice based on the scientific knowledge we have today. This review of the current situations gives considerations which have to be taken into account when getting back to work in plastic surgery with COVID-19 in Europe. At all times, one should be familiar the local and regional infection rates in the community, with particular emphasis on the emergence of second and third waves of the pandemic. Due to the fast-evolving nature of the COVID-19 pandemic the recommendations aim to be rather considerations than fixed guidelines and might need to be revised in near future. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2020        PMID: 32422664     DOI: 10.1055/a-1175-4169

Source DB:  PubMed          Journal:  Handchir Mikrochir Plast Chir        ISSN: 0722-1819            Impact factor:   1.018


  1 in total

1.  [COVID-19 and plastic surgery: aesthetic surgery or essential medical care? - Impact of the COVID-19 pandemic on patient care in the plastic surgery department at an university hospital].

Authors:  Daniel Popp; Christian Smolle; Sebastian P Nischwitz; Isabelle Sawetz; Caroline Schaunig; Raimund Winter; Stephan Spendel; Lars-Peter Kamolz
Journal:  Handchir Mikrochir Plast Chir       Date:  2021-02-02       Impact factor: 1.018

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.